Article
A 24-color metaphase-based radiation assay discriminates heterozygous BRCA2 mutation carriers from controls by chromosomal radiosensitivity.
Breast cancer research and treatment - 1 Aug 2012
Becker Alexandra A, Graeser Monika K, Landwehr Christina, Hilger Thomas, Baus Wolfgang, Wappenschmidt Barbara, Meindl Alfons, Weber Ruthild G, Schmutzler Rita K
Abstract excerpt
Numerous allelic variants identified in the familial breast cancer and DNA repair genes BRCA1 and BRCA2 are of unknown impact on protein function or clinical relevance, referred to as unclassified variants (UCV). Lymphocytes from pathogenic BRCA1/2 mutation carriers exhibit an increased level of chromosomal damage after irradiation. We established a radiation assay for the discrimination of pathogenic BRCA2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.